Securing back-to-back authorizations from two of the world's most demanding regulators -- for a product class where peptide stability, device compatibility and analytical comparability have historically delayed generic entry -- underscores the scientific and quality robustness of Orbicular's program
Boehringer Ingelheim/Eli Lilly), and DAPA-CKD with dapagliflozin (Farxiga
Cejas P, Garcia-Cabezas MA, Casado E, Belda-Iniesta C, De Castro J, Fresno JA, Sereno M, Barriuso J, Espinosa E, Zamora P, et al
The outcome of ICSI is known to be influenced by a myriad of factors
People are suing Novo Nordisk, the manufacturer of Wegovy, for certain harms they suffered while taking the drug